nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—Protein Kinase Inhibitors—Sunitinib—pancreatic cancer	0.519	1	CiPCiCtD
Everolimus—kidney cancer—pancreatic cancer	0.349	1	CtDrD
Everolimus—CYP3A4—Tamoxifen—pancreatic cancer	0.00208	0.24	CbGbCtD
Everolimus—CYP3A4—Erlotinib—pancreatic cancer	0.00177	0.204	CbGbCtD
Everolimus—CYP3A4—Irinotecan—pancreatic cancer	0.0016	0.185	CbGbCtD
Everolimus—CYP3A4—Docetaxel—pancreatic cancer	0.00117	0.135	CbGbCtD
Everolimus—CYP3A4—Sunitinib—pancreatic cancer	0.00117	0.135	CbGbCtD
Everolimus—CYP3A4—Doxorubicin—pancreatic cancer	0.000874	0.101	CbGbCtD
Everolimus—Chest pain—Docetaxel—pancreatic cancer	2.17e-05	0.000266	CcSEcCtD
Everolimus—Myalgia—Docetaxel—pancreatic cancer	2.17e-05	0.000266	CcSEcCtD
Everolimus—Nausea—Sunitinib—pancreatic cancer	2.17e-05	0.000266	CcSEcCtD
Everolimus—Pancytopenia—Doxorubicin—pancreatic cancer	2.17e-05	0.000265	CcSEcCtD
Everolimus—Renal failure—Epirubicin—pancreatic cancer	2.16e-05	0.000265	CcSEcCtD
Everolimus—Asthenia—Irinotecan—pancreatic cancer	2.16e-05	0.000264	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	2.16e-05	0.000264	CcSEcCtD
Everolimus—Stomatitis—Epirubicin—pancreatic cancer	2.14e-05	0.000263	CcSEcCtD
Everolimus—Jaundice—Epirubicin—pancreatic cancer	2.14e-05	0.000263	CcSEcCtD
Everolimus—Urinary tract infection—Epirubicin—pancreatic cancer	2.14e-05	0.000262	CcSEcCtD
Everolimus—Conjunctivitis—Epirubicin—pancreatic cancer	2.14e-05	0.000262	CcSEcCtD
Everolimus—Dysuria—Doxorubicin—pancreatic cancer	2.14e-05	0.000261	CcSEcCtD
Everolimus—Neutropenia—Doxorubicin—pancreatic cancer	2.14e-05	0.000261	CcSEcCtD
Everolimus—Hypersensitivity—Fluorouracil—pancreatic cancer	2.12e-05	0.00026	CcSEcCtD
Everolimus—Dry mouth—Docetaxel—pancreatic cancer	2.12e-05	0.00026	CcSEcCtD
Everolimus—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	2.12e-05	0.00026	CcSEcCtD
Everolimus—Pollakiuria—Doxorubicin—pancreatic cancer	2.11e-05	0.000258	CcSEcCtD
Everolimus—Asthenia—Gemcitabine—pancreatic cancer	2.1e-05	0.000257	CcSEcCtD
Everolimus—Haematuria—Epirubicin—pancreatic cancer	2.1e-05	0.000257	CcSEcCtD
Everolimus—Hepatobiliary disease—Epirubicin—pancreatic cancer	2.08e-05	0.000255	CcSEcCtD
Everolimus—Oedema—Docetaxel—pancreatic cancer	2.08e-05	0.000255	CcSEcCtD
Everolimus—Epistaxis—Epirubicin—pancreatic cancer	2.08e-05	0.000254	CcSEcCtD
Everolimus—Pruritus—Gemcitabine—pancreatic cancer	2.07e-05	0.000254	CcSEcCtD
Everolimus—Infection—Docetaxel—pancreatic cancer	2.07e-05	0.000253	CcSEcCtD
Everolimus—Weight decreased—Doxorubicin—pancreatic cancer	2.07e-05	0.000253	CcSEcCtD
Everolimus—Sinusitis—Epirubicin—pancreatic cancer	2.06e-05	0.000253	CcSEcCtD
Everolimus—Hyperglycaemia—Doxorubicin—pancreatic cancer	2.06e-05	0.000252	CcSEcCtD
Everolimus—Diarrhoea—Irinotecan—pancreatic cancer	2.06e-05	0.000252	CcSEcCtD
Everolimus—Pneumonia—Doxorubicin—pancreatic cancer	2.05e-05	0.000251	CcSEcCtD
Everolimus—Shock—Docetaxel—pancreatic cancer	2.05e-05	0.000251	CcSEcCtD
Everolimus—Nervous system disorder—Docetaxel—pancreatic cancer	2.04e-05	0.00025	CcSEcCtD
Everolimus—Pruritus—Fluorouracil—pancreatic cancer	2.04e-05	0.00025	CcSEcCtD
Everolimus—Thrombocytopenia—Docetaxel—pancreatic cancer	2.04e-05	0.000249	CcSEcCtD
Everolimus—Infestation NOS—Doxorubicin—pancreatic cancer	2.04e-05	0.000249	CcSEcCtD
Everolimus—Infestation—Doxorubicin—pancreatic cancer	2.04e-05	0.000249	CcSEcCtD
Everolimus—Tachycardia—Docetaxel—pancreatic cancer	2.03e-05	0.000249	CcSEcCtD
Everolimus—Skin disorder—Docetaxel—pancreatic cancer	2.02e-05	0.000247	CcSEcCtD
Everolimus—Diarrhoea—Gemcitabine—pancreatic cancer	2.01e-05	0.000246	CcSEcCtD
Everolimus—Renal failure—Doxorubicin—pancreatic cancer	2e-05	0.000245	CcSEcCtD
Everolimus—Dizziness—Irinotecan—pancreatic cancer	1.99e-05	0.000244	CcSEcCtD
Everolimus—Haemoglobin—Epirubicin—pancreatic cancer	1.99e-05	0.000243	CcSEcCtD
Everolimus—Jaundice—Doxorubicin—pancreatic cancer	1.98e-05	0.000243	CcSEcCtD
Everolimus—Stomatitis—Doxorubicin—pancreatic cancer	1.98e-05	0.000243	CcSEcCtD
Everolimus—Anorexia—Docetaxel—pancreatic cancer	1.98e-05	0.000243	CcSEcCtD
Everolimus—Rhinitis—Epirubicin—pancreatic cancer	1.98e-05	0.000242	CcSEcCtD
Everolimus—Urinary tract infection—Doxorubicin—pancreatic cancer	1.98e-05	0.000242	CcSEcCtD
Everolimus—Conjunctivitis—Doxorubicin—pancreatic cancer	1.98e-05	0.000242	CcSEcCtD
Everolimus—Haemorrhage—Epirubicin—pancreatic cancer	1.98e-05	0.000242	CcSEcCtD
Everolimus—Hepatitis—Epirubicin—pancreatic cancer	1.98e-05	0.000242	CcSEcCtD
Everolimus—Diarrhoea—Fluorouracil—pancreatic cancer	1.97e-05	0.000241	CcSEcCtD
Everolimus—Hypoaesthesia—Epirubicin—pancreatic cancer	1.97e-05	0.000241	CcSEcCtD
Everolimus—Pharyngitis—Epirubicin—pancreatic cancer	1.96e-05	0.00024	CcSEcCtD
Everolimus—Urinary tract disorder—Epirubicin—pancreatic cancer	1.95e-05	0.000239	CcSEcCtD
Everolimus—Oedema peripheral—Epirubicin—pancreatic cancer	1.95e-05	0.000238	CcSEcCtD
Everolimus—Hypotension—Docetaxel—pancreatic cancer	1.94e-05	0.000238	CcSEcCtD
Everolimus—Haematuria—Doxorubicin—pancreatic cancer	1.94e-05	0.000238	CcSEcCtD
Everolimus—Connective tissue disorder—Epirubicin—pancreatic cancer	1.94e-05	0.000238	CcSEcCtD
Everolimus—Urethral disorder—Epirubicin—pancreatic cancer	1.94e-05	0.000237	CcSEcCtD
Everolimus—Hepatobiliary disease—Doxorubicin—pancreatic cancer	1.93e-05	0.000236	CcSEcCtD
Everolimus—Epistaxis—Doxorubicin—pancreatic cancer	1.92e-05	0.000235	CcSEcCtD
Everolimus—Vomiting—Irinotecan—pancreatic cancer	1.91e-05	0.000234	CcSEcCtD
Everolimus—Sinusitis—Doxorubicin—pancreatic cancer	1.91e-05	0.000234	CcSEcCtD
Everolimus—Dizziness—Fluorouracil—pancreatic cancer	1.91e-05	0.000233	CcSEcCtD
Everolimus—Rash—Irinotecan—pancreatic cancer	1.9e-05	0.000232	CcSEcCtD
Everolimus—Dermatitis—Irinotecan—pancreatic cancer	1.9e-05	0.000232	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	1.9e-05	0.000232	CcSEcCtD
Everolimus—Headache—Irinotecan—pancreatic cancer	1.89e-05	0.000231	CcSEcCtD
Everolimus—Insomnia—Docetaxel—pancreatic cancer	1.88e-05	0.00023	CcSEcCtD
Everolimus—Paraesthesia—Docetaxel—pancreatic cancer	1.87e-05	0.000229	CcSEcCtD
Everolimus—Vomiting—Gemcitabine—pancreatic cancer	1.86e-05	0.000228	CcSEcCtD
Everolimus—Dyspnoea—Docetaxel—pancreatic cancer	1.86e-05	0.000227	CcSEcCtD
Everolimus—Somnolence—Docetaxel—pancreatic cancer	1.85e-05	0.000226	CcSEcCtD
Everolimus—Rash—Gemcitabine—pancreatic cancer	1.85e-05	0.000226	CcSEcCtD
Everolimus—Dermatitis—Gemcitabine—pancreatic cancer	1.85e-05	0.000226	CcSEcCtD
Everolimus—Eye disorder—Epirubicin—pancreatic cancer	1.85e-05	0.000226	CcSEcCtD
Everolimus—Haemoglobin—Doxorubicin—pancreatic cancer	1.84e-05	0.000225	CcSEcCtD
Everolimus—Headache—Gemcitabine—pancreatic cancer	1.84e-05	0.000225	CcSEcCtD
Everolimus—Flushing—Epirubicin—pancreatic cancer	1.83e-05	0.000224	CcSEcCtD
Everolimus—Cardiac disorder—Epirubicin—pancreatic cancer	1.83e-05	0.000224	CcSEcCtD
Everolimus—Vomiting—Fluorouracil—pancreatic cancer	1.83e-05	0.000224	CcSEcCtD
Everolimus—Rhinitis—Doxorubicin—pancreatic cancer	1.83e-05	0.000224	CcSEcCtD
Everolimus—Dyspepsia—Docetaxel—pancreatic cancer	1.83e-05	0.000224	CcSEcCtD
Everolimus—Haemorrhage—Doxorubicin—pancreatic cancer	1.83e-05	0.000224	CcSEcCtD
Everolimus—Hepatitis—Doxorubicin—pancreatic cancer	1.83e-05	0.000224	CcSEcCtD
Everolimus—Hypoaesthesia—Doxorubicin—pancreatic cancer	1.82e-05	0.000223	CcSEcCtD
Everolimus—Rash—Fluorouracil—pancreatic cancer	1.82e-05	0.000222	CcSEcCtD
Everolimus—Dermatitis—Fluorouracil—pancreatic cancer	1.82e-05	0.000222	CcSEcCtD
Everolimus—Pharyngitis—Doxorubicin—pancreatic cancer	1.81e-05	0.000222	CcSEcCtD
Everolimus—Decreased appetite—Docetaxel—pancreatic cancer	1.81e-05	0.000221	CcSEcCtD
Everolimus—Headache—Fluorouracil—pancreatic cancer	1.81e-05	0.000221	CcSEcCtD
Everolimus—Urinary tract disorder—Doxorubicin—pancreatic cancer	1.81e-05	0.000221	CcSEcCtD
Everolimus—Oedema peripheral—Doxorubicin—pancreatic cancer	1.8e-05	0.00022	CcSEcCtD
Everolimus—Gastrointestinal disorder—Docetaxel—pancreatic cancer	1.8e-05	0.00022	CcSEcCtD
Everolimus—Connective tissue disorder—Doxorubicin—pancreatic cancer	1.8e-05	0.00022	CcSEcCtD
Everolimus—Fatigue—Docetaxel—pancreatic cancer	1.79e-05	0.00022	CcSEcCtD
Everolimus—Angiopathy—Epirubicin—pancreatic cancer	1.79e-05	0.000219	CcSEcCtD
Everolimus—Urethral disorder—Doxorubicin—pancreatic cancer	1.79e-05	0.000219	CcSEcCtD
Everolimus—Nausea—Irinotecan—pancreatic cancer	1.79e-05	0.000219	CcSEcCtD
Everolimus—Immune system disorder—Epirubicin—pancreatic cancer	1.78e-05	0.000218	CcSEcCtD
Everolimus—Mediastinal disorder—Epirubicin—pancreatic cancer	1.78e-05	0.000218	CcSEcCtD
Everolimus—Constipation—Docetaxel—pancreatic cancer	1.78e-05	0.000218	CcSEcCtD
Everolimus—Pain—Docetaxel—pancreatic cancer	1.78e-05	0.000218	CcSEcCtD
Everolimus—Chills—Epirubicin—pancreatic cancer	1.77e-05	0.000217	CcSEcCtD
Everolimus—Alopecia—Epirubicin—pancreatic cancer	1.75e-05	0.000214	CcSEcCtD
Everolimus—Nausea—Gemcitabine—pancreatic cancer	1.74e-05	0.000213	CcSEcCtD
Everolimus—Mental disorder—Epirubicin—pancreatic cancer	1.73e-05	0.000212	CcSEcCtD
Everolimus—Malnutrition—Epirubicin—pancreatic cancer	1.72e-05	0.00021	CcSEcCtD
Everolimus—Erythema—Epirubicin—pancreatic cancer	1.72e-05	0.00021	CcSEcCtD
Everolimus—Feeling abnormal—Docetaxel—pancreatic cancer	1.71e-05	0.00021	CcSEcCtD
Everolimus—Nausea—Fluorouracil—pancreatic cancer	1.71e-05	0.00021	CcSEcCtD
Everolimus—Eye disorder—Doxorubicin—pancreatic cancer	1.71e-05	0.000209	CcSEcCtD
Everolimus—Gastrointestinal pain—Docetaxel—pancreatic cancer	1.7e-05	0.000208	CcSEcCtD
Everolimus—Cardiac disorder—Doxorubicin—pancreatic cancer	1.7e-05	0.000208	CcSEcCtD
Everolimus—Flushing—Doxorubicin—pancreatic cancer	1.7e-05	0.000208	CcSEcCtD
Everolimus—Flatulence—Epirubicin—pancreatic cancer	1.69e-05	0.000207	CcSEcCtD
Everolimus—Dysgeusia—Epirubicin—pancreatic cancer	1.68e-05	0.000206	CcSEcCtD
Everolimus—Back pain—Epirubicin—pancreatic cancer	1.66e-05	0.000204	CcSEcCtD
Everolimus—Angiopathy—Doxorubicin—pancreatic cancer	1.66e-05	0.000203	CcSEcCtD
Everolimus—Muscle spasms—Epirubicin—pancreatic cancer	1.65e-05	0.000202	CcSEcCtD
Everolimus—Immune system disorder—Doxorubicin—pancreatic cancer	1.65e-05	0.000202	CcSEcCtD
Everolimus—Mediastinal disorder—Doxorubicin—pancreatic cancer	1.65e-05	0.000202	CcSEcCtD
Everolimus—Body temperature increased—Docetaxel—pancreatic cancer	1.64e-05	0.000201	CcSEcCtD
Everolimus—Abdominal pain—Docetaxel—pancreatic cancer	1.64e-05	0.000201	CcSEcCtD
Everolimus—Chills—Doxorubicin—pancreatic cancer	1.64e-05	0.000201	CcSEcCtD
Everolimus—Vision blurred—Epirubicin—pancreatic cancer	1.62e-05	0.000198	CcSEcCtD
Everolimus—Alopecia—Doxorubicin—pancreatic cancer	1.62e-05	0.000198	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—PTEN—pancreatic cancer	1.61e-05	0.00038	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—pancreatic cancer	1.6e-05	0.000379	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—AKT1—pancreatic cancer	1.6e-05	0.000379	CbGpPWpGaD
Everolimus—MTOR—Disease—IAPP—pancreatic cancer	1.6e-05	0.000379	CbGpPWpGaD
Everolimus—Mental disorder—Doxorubicin—pancreatic cancer	1.6e-05	0.000196	CcSEcCtD
Everolimus—Ill-defined disorder—Epirubicin—pancreatic cancer	1.6e-05	0.000195	CcSEcCtD
Everolimus—Erythema—Doxorubicin—pancreatic cancer	1.59e-05	0.000195	CcSEcCtD
Everolimus—Malnutrition—Doxorubicin—pancreatic cancer	1.59e-05	0.000195	CcSEcCtD
Everolimus—Anaemia—Epirubicin—pancreatic cancer	1.59e-05	0.000195	CcSEcCtD
Everolimus—Agitation—Epirubicin—pancreatic cancer	1.58e-05	0.000193	CcSEcCtD
Everolimus—MTOR—Innate Immune System—BCL2L1—pancreatic cancer	1.58e-05	0.000373	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—DTX4—pancreatic cancer	1.57e-05	0.000371	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GLI1—pancreatic cancer	1.57e-05	0.000371	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TERT—pancreatic cancer	1.57e-05	0.000371	CbGpPWpGaD
Everolimus—Flatulence—Doxorubicin—pancreatic cancer	1.57e-05	0.000192	CcSEcCtD
Everolimus—MTOR—Innate Immune System—TSC2—pancreatic cancer	1.57e-05	0.00037	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—GCG—pancreatic cancer	1.56e-05	0.000369	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—AKT1—pancreatic cancer	1.56e-05	0.000369	CbGpPWpGaD
Everolimus—Dysgeusia—Doxorubicin—pancreatic cancer	1.56e-05	0.000191	CcSEcCtD
Everolimus—Malaise—Epirubicin—pancreatic cancer	1.55e-05	0.00019	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—VEGFA—pancreatic cancer	1.55e-05	0.000366	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—pancreatic cancer	1.54e-05	0.000365	CbGpPWpGaD
Everolimus—Syncope—Epirubicin—pancreatic cancer	1.54e-05	0.000189	CcSEcCtD
Everolimus—MTOR—B Cell Activation—PIK3CA—pancreatic cancer	1.54e-05	0.000364	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—HRAS—pancreatic cancer	1.54e-05	0.000364	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—pancreatic cancer	1.54e-05	0.000364	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—HRAS—pancreatic cancer	1.54e-05	0.000364	CbGpPWpGaD
Everolimus—Leukopenia—Epirubicin—pancreatic cancer	1.54e-05	0.000188	CcSEcCtD
Everolimus—Back pain—Doxorubicin—pancreatic cancer	1.54e-05	0.000188	CcSEcCtD
Everolimus—MTOR—Disease—HSPA1B—pancreatic cancer	1.54e-05	0.000364	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—AKT1—pancreatic cancer	1.54e-05	0.000363	CbGpPWpGaD
Everolimus—Hypersensitivity—Docetaxel—pancreatic cancer	1.53e-05	0.000188	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—STAT3—pancreatic cancer	1.53e-05	0.000362	CbGpPWpGaD
Everolimus—Muscle spasms—Doxorubicin—pancreatic cancer	1.53e-05	0.000187	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—PPP2R5B—pancreatic cancer	1.53e-05	0.000361	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NRP1—pancreatic cancer	1.53e-05	0.000361	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—HRAS—pancreatic cancer	1.53e-05	0.000361	CbGpPWpGaD
Everolimus—Palpitations—Epirubicin—pancreatic cancer	1.52e-05	0.000186	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—HRAS—pancreatic cancer	1.51e-05	0.000357	CbGpPWpGaD
Everolimus—Loss of consciousness—Epirubicin—pancreatic cancer	1.51e-05	0.000185	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—HRAS—pancreatic cancer	1.51e-05	0.000356	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—TSC2—pancreatic cancer	1.51e-05	0.000356	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HIF1A—pancreatic cancer	1.5e-05	0.000355	CbGpPWpGaD
Everolimus—Cough—Epirubicin—pancreatic cancer	1.5e-05	0.000184	CcSEcCtD
Everolimus—Vision blurred—Doxorubicin—pancreatic cancer	1.5e-05	0.000184	CcSEcCtD
Everolimus—FKBP1A—Disease—TSC2—pancreatic cancer	1.5e-05	0.000354	CbGpPWpGaD
Everolimus—Asthenia—Docetaxel—pancreatic cancer	1.49e-05	0.000183	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—SRC—pancreatic cancer	1.49e-05	0.000352	CbGpPWpGaD
Everolimus—Convulsion—Epirubicin—pancreatic cancer	1.49e-05	0.000182	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—AGTR1—pancreatic cancer	1.49e-05	0.000352	CbGpPWpGaD
Everolimus—Hypertension—Epirubicin—pancreatic cancer	1.48e-05	0.000182	CcSEcCtD
Everolimus—Ill-defined disorder—Doxorubicin—pancreatic cancer	1.48e-05	0.000181	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—PIK3CA—pancreatic cancer	1.47e-05	0.000348	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—AKT1—pancreatic cancer	1.47e-05	0.000348	CbGpPWpGaD
Everolimus—Pruritus—Docetaxel—pancreatic cancer	1.47e-05	0.00018	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—HEY2—pancreatic cancer	1.47e-05	0.000348	CbGpPWpGaD
Everolimus—Anaemia—Doxorubicin—pancreatic cancer	1.47e-05	0.00018	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—STK11—pancreatic cancer	1.47e-05	0.000347	CbGpPWpGaD
Everolimus—FKBP1A—Disease—APOE—pancreatic cancer	1.47e-05	0.000347	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—AKT1—pancreatic cancer	1.47e-05	0.000347	CbGpPWpGaD
Everolimus—Arthralgia—Epirubicin—pancreatic cancer	1.46e-05	0.000179	CcSEcCtD
Everolimus—Chest pain—Epirubicin—pancreatic cancer	1.46e-05	0.000179	CcSEcCtD
Everolimus—Myalgia—Epirubicin—pancreatic cancer	1.46e-05	0.000179	CcSEcCtD
Everolimus—Agitation—Doxorubicin—pancreatic cancer	1.46e-05	0.000179	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR—AKT1—pancreatic cancer	1.46e-05	0.000345	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—pancreatic cancer	1.46e-05	0.000345	CbGpPWpGaD
Everolimus—Anxiety—Epirubicin—pancreatic cancer	1.46e-05	0.000179	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	1.45e-05	0.000178	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—AKT1—pancreatic cancer	1.45e-05	0.000343	CbGpPWpGaD
Everolimus—Discomfort—Epirubicin—pancreatic cancer	1.45e-05	0.000177	CcSEcCtD
Everolimus—MTOR—DAP12 signaling—AKT1—pancreatic cancer	1.45e-05	0.000342	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GAST—pancreatic cancer	1.44e-05	0.00034	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—STAT3—pancreatic cancer	1.44e-05	0.00034	CbGpPWpGaD
Everolimus—Malaise—Doxorubicin—pancreatic cancer	1.43e-05	0.000176	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—NRAS—pancreatic cancer	1.43e-05	0.000339	CbGpPWpGaD
Everolimus—Dry mouth—Epirubicin—pancreatic cancer	1.43e-05	0.000175	CcSEcCtD
Everolimus—MTOR—Innate Immune System—NFKBIA—pancreatic cancer	1.43e-05	0.000338	CbGpPWpGaD
Everolimus—Syncope—Doxorubicin—pancreatic cancer	1.43e-05	0.000175	CcSEcCtD
Everolimus—MTOR—B Cell Activation—HRAS—pancreatic cancer	1.43e-05	0.000337	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—pancreatic cancer	1.42e-05	0.000337	CbGpPWpGaD
Everolimus—Leukopenia—Doxorubicin—pancreatic cancer	1.42e-05	0.000174	CcSEcCtD
Everolimus—Diarrhoea—Docetaxel—pancreatic cancer	1.42e-05	0.000174	CcSEcCtD
Everolimus—MTOR—Immune System—CD44—pancreatic cancer	1.42e-05	0.000335	CbGpPWpGaD
Everolimus—Palpitations—Doxorubicin—pancreatic cancer	1.41e-05	0.000172	CcSEcCtD
Everolimus—Oedema—Epirubicin—pancreatic cancer	1.4e-05	0.000172	CcSEcCtD
Everolimus—Loss of consciousness—Doxorubicin—pancreatic cancer	1.4e-05	0.000171	CcSEcCtD
Everolimus—Infection—Epirubicin—pancreatic cancer	1.39e-05	0.000171	CcSEcCtD
Everolimus—Cough—Doxorubicin—pancreatic cancer	1.39e-05	0.00017	CcSEcCtD
Everolimus—Shock—Epirubicin—pancreatic cancer	1.38e-05	0.000169	CcSEcCtD
Everolimus—Convulsion—Doxorubicin—pancreatic cancer	1.38e-05	0.000169	CcSEcCtD
Everolimus—MTOR—Disease—JAG1—pancreatic cancer	1.38e-05	0.000325	CbGpPWpGaD
Everolimus—Nervous system disorder—Epirubicin—pancreatic cancer	1.38e-05	0.000168	CcSEcCtD
Everolimus—Dizziness—Docetaxel—pancreatic cancer	1.38e-05	0.000168	CcSEcCtD
Everolimus—Thrombocytopenia—Epirubicin—pancreatic cancer	1.37e-05	0.000168	CcSEcCtD
Everolimus—Hypertension—Doxorubicin—pancreatic cancer	1.37e-05	0.000168	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—NFKBIA—pancreatic cancer	1.37e-05	0.000324	CbGpPWpGaD
Everolimus—MTOR—Immune System—IFNA1—pancreatic cancer	1.37e-05	0.000324	CbGpPWpGaD
Everolimus—Tachycardia—Epirubicin—pancreatic cancer	1.37e-05	0.000168	CcSEcCtD
Everolimus—MTOR—Innate Immune System—EGF—pancreatic cancer	1.37e-05	0.000323	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—pancreatic cancer	1.36e-05	0.000322	CbGpPWpGaD
Everolimus—Skin disorder—Epirubicin—pancreatic cancer	1.36e-05	0.000167	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—SCT—pancreatic cancer	1.36e-05	0.000322	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HEY1—pancreatic cancer	1.36e-05	0.000322	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—pancreatic cancer	1.36e-05	0.000321	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—AKT1—pancreatic cancer	1.36e-05	0.000321	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—AKT1—pancreatic cancer	1.36e-05	0.000321	CbGpPWpGaD
Everolimus—Hyperhidrosis—Epirubicin—pancreatic cancer	1.36e-05	0.000166	CcSEcCtD
Everolimus—Chest pain—Doxorubicin—pancreatic cancer	1.35e-05	0.000166	CcSEcCtD
Everolimus—Arthralgia—Doxorubicin—pancreatic cancer	1.35e-05	0.000166	CcSEcCtD
Everolimus—Myalgia—Doxorubicin—pancreatic cancer	1.35e-05	0.000166	CcSEcCtD
Everolimus—FKBP1A—Disease—NOTCH1—pancreatic cancer	1.35e-05	0.00032	CbGpPWpGaD
Everolimus—Anxiety—Doxorubicin—pancreatic cancer	1.35e-05	0.000165	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—AKT1—pancreatic cancer	1.35e-05	0.000318	CbGpPWpGaD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	1.35e-05	0.000165	CcSEcCtD
Everolimus—Discomfort—Doxorubicin—pancreatic cancer	1.34e-05	0.000164	CcSEcCtD
Everolimus—Anorexia—Epirubicin—pancreatic cancer	1.34e-05	0.000164	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—AKT1—pancreatic cancer	1.34e-05	0.000316	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—AKT1—pancreatic cancer	1.33e-05	0.000314	CbGpPWpGaD
Everolimus—Dry mouth—Doxorubicin—pancreatic cancer	1.32e-05	0.000162	CcSEcCtD
Everolimus—Vomiting—Docetaxel—pancreatic cancer	1.32e-05	0.000162	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—EGF—pancreatic cancer	1.31e-05	0.000311	CbGpPWpGaD
Everolimus—Rash—Docetaxel—pancreatic cancer	1.31e-05	0.000161	CcSEcCtD
Everolimus—Hypotension—Epirubicin—pancreatic cancer	1.31e-05	0.000161	CcSEcCtD
Everolimus—Dermatitis—Docetaxel—pancreatic cancer	1.31e-05	0.00016	CcSEcCtD
Everolimus—FKBP1A—Disease—EGF—pancreatic cancer	1.31e-05	0.000309	CbGpPWpGaD
Everolimus—MTOR—Disease—CD44—pancreatic cancer	1.31e-05	0.000309	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—EGFR—pancreatic cancer	1.31e-05	0.000309	CbGpPWpGaD
Everolimus—Headache—Docetaxel—pancreatic cancer	1.3e-05	0.00016	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—CCK—pancreatic cancer	1.3e-05	0.000307	CbGpPWpGaD
Everolimus—MTOR—Disease—HSPA1A—pancreatic cancer	1.3e-05	0.000307	CbGpPWpGaD
Everolimus—Oedema—Doxorubicin—pancreatic cancer	1.3e-05	0.000159	CcSEcCtD
Everolimus—Infection—Doxorubicin—pancreatic cancer	1.29e-05	0.000158	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—SMAD4—pancreatic cancer	1.29e-05	0.000304	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	1.28e-05	0.000157	CcSEcCtD
Everolimus—Shock—Doxorubicin—pancreatic cancer	1.28e-05	0.000156	CcSEcCtD
Everolimus—MTOR—Immune System—IFNA2—pancreatic cancer	1.28e-05	0.000302	CbGpPWpGaD
Everolimus—Nervous system disorder—Doxorubicin—pancreatic cancer	1.27e-05	0.000156	CcSEcCtD
Everolimus—Thrombocytopenia—Doxorubicin—pancreatic cancer	1.27e-05	0.000156	CcSEcCtD
Everolimus—Insomnia—Epirubicin—pancreatic cancer	1.27e-05	0.000155	CcSEcCtD
Everolimus—Tachycardia—Doxorubicin—pancreatic cancer	1.27e-05	0.000155	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—CNR2—pancreatic cancer	1.27e-05	0.000299	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—GLP1R—pancreatic cancer	1.27e-05	0.000299	CbGpPWpGaD
Everolimus—Skin disorder—Doxorubicin—pancreatic cancer	1.26e-05	0.000154	CcSEcCtD
Everolimus—Paraesthesia—Epirubicin—pancreatic cancer	1.26e-05	0.000154	CcSEcCtD
Everolimus—MTOR—B Cell Activation—AKT1—pancreatic cancer	1.26e-05	0.000297	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HES1—pancreatic cancer	1.26e-05	0.000297	CbGpPWpGaD
Everolimus—Hyperhidrosis—Doxorubicin—pancreatic cancer	1.26e-05	0.000154	CcSEcCtD
Everolimus—Dyspnoea—Epirubicin—pancreatic cancer	1.25e-05	0.000153	CcSEcCtD
Everolimus—Somnolence—Epirubicin—pancreatic cancer	1.25e-05	0.000153	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—CCKAR—pancreatic cancer	1.25e-05	0.000295	CbGpPWpGaD
Everolimus—Anorexia—Doxorubicin—pancreatic cancer	1.24e-05	0.000152	CcSEcCtD
Everolimus—Nausea—Docetaxel—pancreatic cancer	1.24e-05	0.000151	CcSEcCtD
Everolimus—Dyspepsia—Epirubicin—pancreatic cancer	1.24e-05	0.000151	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—KRAS—pancreatic cancer	1.23e-05	0.000292	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CDH1—pancreatic cancer	1.22e-05	0.000289	CbGpPWpGaD
Everolimus—Decreased appetite—Epirubicin—pancreatic cancer	1.22e-05	0.000149	CcSEcCtD
Everolimus—MTOR—Innate Immune System—PIK3CD—pancreatic cancer	1.22e-05	0.000288	CbGpPWpGaD
Everolimus—Hypotension—Doxorubicin—pancreatic cancer	1.21e-05	0.000149	CcSEcCtD
Everolimus—Gastrointestinal disorder—Epirubicin—pancreatic cancer	1.21e-05	0.000148	CcSEcCtD
Everolimus—Fatigue—Epirubicin—pancreatic cancer	1.21e-05	0.000148	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—JAG2—pancreatic cancer	1.21e-05	0.000286	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—pancreatic cancer	1.2e-05	0.000285	CbGpPWpGaD
Everolimus—Constipation—Epirubicin—pancreatic cancer	1.2e-05	0.000147	CcSEcCtD
Everolimus—Pain—Epirubicin—pancreatic cancer	1.2e-05	0.000147	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—MEN1—pancreatic cancer	1.19e-05	0.000282	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	1.18e-05	0.000145	CcSEcCtD
Everolimus—Insomnia—Doxorubicin—pancreatic cancer	1.17e-05	0.000144	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—TP53—pancreatic cancer	1.17e-05	0.000276	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PIK3CD—pancreatic cancer	1.17e-05	0.000276	CbGpPWpGaD
Everolimus—Paraesthesia—Doxorubicin—pancreatic cancer	1.17e-05	0.000143	CcSEcCtD
Everolimus—FKBP1A—Disease—PIK3CD—pancreatic cancer	1.16e-05	0.000275	CbGpPWpGaD
Everolimus—Dyspnoea—Doxorubicin—pancreatic cancer	1.16e-05	0.000142	CcSEcCtD
Everolimus—Feeling abnormal—Epirubicin—pancreatic cancer	1.16e-05	0.000142	CcSEcCtD
Everolimus—Somnolence—Doxorubicin—pancreatic cancer	1.15e-05	0.000141	CcSEcCtD
Everolimus—Gastrointestinal pain—Epirubicin—pancreatic cancer	1.15e-05	0.00014	CcSEcCtD
Everolimus—Dyspepsia—Doxorubicin—pancreatic cancer	1.14e-05	0.00014	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—SHH—pancreatic cancer	1.14e-05	0.000269	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—PIK3CA—pancreatic cancer	1.13e-05	0.000268	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOTCH4—pancreatic cancer	1.13e-05	0.000267	CbGpPWpGaD
Everolimus—Decreased appetite—Doxorubicin—pancreatic cancer	1.13e-05	0.000138	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—IAPP—pancreatic cancer	1.12e-05	0.000265	CbGpPWpGaD
Everolimus—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	1.12e-05	0.000137	CcSEcCtD
Everolimus—Fatigue—Doxorubicin—pancreatic cancer	1.12e-05	0.000137	CcSEcCtD
Everolimus—Constipation—Doxorubicin—pancreatic cancer	1.11e-05	0.000136	CcSEcCtD
Everolimus—Pain—Doxorubicin—pancreatic cancer	1.11e-05	0.000136	CcSEcCtD
Everolimus—Body temperature increased—Epirubicin—pancreatic cancer	1.11e-05	0.000136	CcSEcCtD
Everolimus—Abdominal pain—Epirubicin—pancreatic cancer	1.11e-05	0.000136	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—TERT—pancreatic cancer	1.1e-05	0.00026	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTHLH—pancreatic cancer	1.08e-05	0.000255	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTCH1—pancreatic cancer	1.08e-05	0.000255	CbGpPWpGaD
Everolimus—Feeling abnormal—Doxorubicin—pancreatic cancer	1.07e-05	0.000131	CcSEcCtD
Everolimus—Gastrointestinal pain—Doxorubicin—pancreatic cancer	1.06e-05	0.00013	CcSEcCtD
Everolimus—MTOR—Innate Immune System—PIK3CB—pancreatic cancer	1.06e-05	0.000251	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HIF1A—pancreatic cancer	1.05e-05	0.000249	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TSC2—pancreatic cancer	1.05e-05	0.000248	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—HRAS—pancreatic cancer	1.05e-05	0.000248	CbGpPWpGaD
Everolimus—Hypersensitivity—Epirubicin—pancreatic cancer	1.03e-05	0.000127	CcSEcCtD
Everolimus—MTOR—Disease—SMAD4—pancreatic cancer	1.03e-05	0.000244	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—APOE—pancreatic cancer	1.03e-05	0.000243	CbGpPWpGaD
Everolimus—Abdominal pain—Doxorubicin—pancreatic cancer	1.03e-05	0.000126	CcSEcCtD
Everolimus—Body temperature increased—Doxorubicin—pancreatic cancer	1.03e-05	0.000126	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—PIK3CB—pancreatic cancer	1.02e-05	0.000241	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PIK3CB—pancreatic cancer	1.01e-05	0.00024	CbGpPWpGaD
Everolimus—MTOR—Disease—HES1—pancreatic cancer	1.01e-05	0.000238	CbGpPWpGaD
Everolimus—Asthenia—Epirubicin—pancreatic cancer	1.01e-05	0.000123	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—KDR—pancreatic cancer	1.01e-05	0.000238	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTGS2—pancreatic cancer	1.01e-05	0.000238	CbGpPWpGaD
Everolimus—Pruritus—Epirubicin—pancreatic cancer	9.93e-06	0.000122	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—SST—pancreatic cancer	9.85e-06	0.000233	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—JAG1—pancreatic cancer	9.64e-06	0.000228	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOTCH3—pancreatic cancer	9.6e-06	0.000227	CbGpPWpGaD
Everolimus—Diarrhoea—Epirubicin—pancreatic cancer	9.6e-06	0.000118	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—NFKBIA—pancreatic cancer	9.57e-06	0.000226	CbGpPWpGaD
Everolimus—Hypersensitivity—Doxorubicin—pancreatic cancer	9.57e-06	0.000117	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—NOTCH1—pancreatic cancer	9.48e-06	0.000224	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CTNNB1—pancreatic cancer	9.41e-06	0.000222	CbGpPWpGaD
Everolimus—Asthenia—Doxorubicin—pancreatic cancer	9.32e-06	0.000114	CcSEcCtD
Everolimus—Dizziness—Epirubicin—pancreatic cancer	9.28e-06	0.000114	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—PIK3CG—pancreatic cancer	9.27e-06	0.000219	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—AKT1—pancreatic cancer	9.26e-06	0.000219	CbGpPWpGaD
Everolimus—MTOR—Immune System—BCL2L1—pancreatic cancer	9.19e-06	0.000217	CbGpPWpGaD
Everolimus—Pruritus—Doxorubicin—pancreatic cancer	9.19e-06	0.000112	CcSEcCtD
Everolimus—MTOR—Innate Immune System—PTEN—pancreatic cancer	9.17e-06	0.000217	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EGF—pancreatic cancer	9.16e-06	0.000217	CbGpPWpGaD
Everolimus—MTOR—Immune System—TSC2—pancreatic cancer	9.13e-06	0.000216	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CNR1—pancreatic cancer	9.09e-06	0.000215	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CTNNB1—pancreatic cancer	8.99e-06	0.000213	CbGpPWpGaD
Everolimus—Vomiting—Epirubicin—pancreatic cancer	8.92e-06	0.000109	CcSEcCtD
Everolimus—Diarrhoea—Doxorubicin—pancreatic cancer	8.88e-06	0.000109	CcSEcCtD
Everolimus—Rash—Epirubicin—pancreatic cancer	8.85e-06	0.000108	CcSEcCtD
Everolimus—Dermatitis—Epirubicin—pancreatic cancer	8.84e-06	0.000108	CcSEcCtD
Everolimus—MTOR—Disease—TERT—pancreatic cancer	8.84e-06	0.000209	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PTEN—pancreatic cancer	8.8e-06	0.000208	CbGpPWpGaD
Everolimus—Headache—Epirubicin—pancreatic cancer	8.79e-06	0.000108	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—GCG—pancreatic cancer	8.78e-06	0.000208	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PTEN—pancreatic cancer	8.77e-06	0.000207	CbGpPWpGaD
Everolimus—Dizziness—Doxorubicin—pancreatic cancer	8.59e-06	0.000105	CcSEcCtD
Everolimus—MTOR—Innate Immune System—SRC—pancreatic cancer	8.5e-06	0.000201	CbGpPWpGaD
Everolimus—MTOR—Disease—HIF1A—pancreatic cancer	8.45e-06	0.0002	CbGpPWpGaD
Everolimus—MTOR—Disease—TSC2—pancreatic cancer	8.43e-06	0.000199	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AGTR1—pancreatic cancer	8.38e-06	0.000198	CbGpPWpGaD
Everolimus—Nausea—Epirubicin—pancreatic cancer	8.34e-06	0.000102	CcSEcCtD
Everolimus—MTOR—Immune System—NFKBIA—pancreatic cancer	8.33e-06	0.000197	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—STK11—pancreatic cancer	8.26e-06	0.000195	CbGpPWpGaD
Everolimus—Vomiting—Doxorubicin—pancreatic cancer	8.26e-06	0.000101	CcSEcCtD
Everolimus—MTOR—Disease—APOE—pancreatic cancer	8.25e-06	0.000195	CbGpPWpGaD
Everolimus—Rash—Doxorubicin—pancreatic cancer	8.19e-06	0.0001	CcSEcCtD
Everolimus—Dermatitis—Doxorubicin—pancreatic cancer	8.18e-06	0.0001	CcSEcCtD
Everolimus—MTOR—Innate Immune System—NRAS—pancreatic cancer	8.18e-06	0.000193	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—SRC—pancreatic cancer	8.16e-06	0.000193	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CD—pancreatic cancer	8.15e-06	0.000193	CbGpPWpGaD
Everolimus—Headache—Doxorubicin—pancreatic cancer	8.14e-06	9.96e-05	CcSEcCtD
Everolimus—FKBP1A—Disease—SRC—pancreatic cancer	8.13e-06	0.000192	CbGpPWpGaD
Everolimus—MTOR—Immune System—EGF—pancreatic cancer	7.97e-06	0.000188	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—NRAS—pancreatic cancer	7.85e-06	0.000186	CbGpPWpGaD
Everolimus—FKBP1A—Disease—STAT3—pancreatic cancer	7.84e-06	0.000185	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NRAS—pancreatic cancer	7.82e-06	0.000185	CbGpPWpGaD
Everolimus—Nausea—Doxorubicin—pancreatic cancer	7.71e-06	9.44e-05	CcSEcCtD
Everolimus—MTOR—Disease—NOTCH1—pancreatic cancer	7.61e-06	0.00018	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—EGFR—pancreatic cancer	7.45e-06	0.000176	CbGpPWpGaD
Everolimus—MTOR—Immune System—CDH1—pancreatic cancer	7.42e-06	0.000175	CbGpPWpGaD
Everolimus—MTOR—Disease—EGF—pancreatic cancer	7.36e-06	0.000174	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MYC—pancreatic cancer	7.28e-06	0.000172	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TGFB1—pancreatic cancer	7.27e-06	0.000172	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SMAD4—pancreatic cancer	7.23e-06	0.000171	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—EGFR—pancreatic cancer	7.16e-06	0.000169	CbGpPWpGaD
Everolimus—FKBP1A—Disease—EGFR—pancreatic cancer	7.13e-06	0.000168	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CB—pancreatic cancer	7.1e-06	0.000168	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CD—pancreatic cancer	7.09e-06	0.000168	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HES1—pancreatic cancer	7.06e-06	0.000167	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—KRAS—pancreatic cancer	7.04e-06	0.000166	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CXCL8—pancreatic cancer	6.83e-06	0.000161	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—KRAS—pancreatic cancer	6.76e-06	0.00016	CbGpPWpGaD
Everolimus—FKBP1A—Disease—KRAS—pancreatic cancer	6.73e-06	0.000159	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PRSS1—pancreatic cancer	6.58e-06	0.000155	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CD—pancreatic cancer	6.55e-06	0.000155	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CASP3—pancreatic cancer	6.53e-06	0.000154	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PIK3CA—pancreatic cancer	6.47e-06	0.000153	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCND1—pancreatic cancer	6.36e-06	0.00015	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CTNNB1—pancreatic cancer	6.3e-06	0.000149	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PIK3CA—pancreatic cancer	6.21e-06	0.000147	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TERT—pancreatic cancer	6.19e-06	0.000146	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PIK3CA—pancreatic cancer	6.18e-06	0.000146	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CB—pancreatic cancer	6.18e-06	0.000146	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MMP9—pancreatic cancer	6.17e-06	0.000146	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PTEN—pancreatic cancer	6.14e-06	0.000145	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—HRAS—pancreatic cancer	5.98e-06	0.000141	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HIF1A—pancreatic cancer	5.92e-06	0.00014	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TSC2—pancreatic cancer	5.9e-06	0.00014	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—APOE—pancreatic cancer	5.78e-06	0.000137	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HRAS—pancreatic cancer	5.75e-06	0.000136	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HRAS—pancreatic cancer	5.72e-06	0.000135	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CB—pancreatic cancer	5.71e-06	0.000135	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ARG2—pancreatic cancer	5.71e-06	0.000135	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SRC—pancreatic cancer	5.69e-06	0.000135	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KDR—pancreatic cancer	5.66e-06	0.000134	CbGpPWpGaD
Everolimus—MTOR—Disease—PTGS2—pancreatic cancer	5.65e-06	0.000134	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VEGFA—pancreatic cancer	5.54e-06	0.000131	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—STAT3—pancreatic cancer	5.49e-06	0.00013	CbGpPWpGaD
Everolimus—MTOR—Immune System—CTNNB1—pancreatic cancer	5.48e-06	0.000129	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NRAS—pancreatic cancer	5.48e-06	0.000129	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NFKBIA—pancreatic cancer	5.38e-06	0.000127	CbGpPWpGaD
Everolimus—MTOR—Immune System—PTEN—pancreatic cancer	5.34e-06	0.000126	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOTCH1—pancreatic cancer	5.33e-06	0.000126	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—AKT1—pancreatic cancer	5.28e-06	0.000125	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CG—pancreatic cancer	5.21e-06	0.000123	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EGF—pancreatic cancer	5.15e-06	0.000122	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MYC—pancreatic cancer	5.1e-06	0.000121	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TGFB1—pancreatic cancer	5.09e-06	0.00012	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—AKT1—pancreatic cancer	5.07e-06	0.00012	CbGpPWpGaD
Everolimus—MTOR—Disease—CTNNB1—pancreatic cancer	5.06e-06	0.00012	CbGpPWpGaD
Everolimus—FKBP1A—Disease—AKT1—pancreatic cancer	5.05e-06	0.000119	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EGFR—pancreatic cancer	4.99e-06	0.000118	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TYMP—pancreatic cancer	4.99e-06	0.000118	CbGpPWpGaD
Everolimus—MTOR—Immune System—SRC—pancreatic cancer	4.95e-06	0.000117	CbGpPWpGaD
Everolimus—MTOR—Disease—PTEN—pancreatic cancer	4.93e-06	0.000116	CbGpPWpGaD
Everolimus—MTOR—Immune System—STAT3—pancreatic cancer	4.78e-06	0.000113	CbGpPWpGaD
Everolimus—MTOR—Immune System—NRAS—pancreatic cancer	4.76e-06	0.000113	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KRAS—pancreatic cancer	4.71e-06	0.000111	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CD—pancreatic cancer	4.58e-06	0.000108	CbGpPWpGaD
Everolimus—MTOR—Disease—SRC—pancreatic cancer	4.57e-06	0.000108	CbGpPWpGaD
Everolimus—MTOR—Disease—STAT3—pancreatic cancer	4.41e-06	0.000104	CbGpPWpGaD
Everolimus—MTOR—Disease—NRAS—pancreatic cancer	4.4e-06	0.000104	CbGpPWpGaD
Everolimus—MTOR—Immune System—EGFR—pancreatic cancer	4.34e-06	0.000103	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—PIK3CA—pancreatic cancer	4.33e-06	0.000102	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—pancreatic cancer	4.19e-06	9.9e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—KRAS—pancreatic cancer	4.1e-06	9.69e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—MYC—pancreatic cancer	4.1e-06	9.68e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—TGFB1—pancreatic cancer	4.09e-06	9.66e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GLP1R—pancreatic cancer	4.02e-06	9.5e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—EGFR—pancreatic cancer	4.01e-06	9.47e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HRAS—pancreatic cancer	4.01e-06	9.47e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CB—pancreatic cancer	4e-06	9.44e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—DPYD—pancreatic cancer	3.95e-06	9.34e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCL8—pancreatic cancer	3.84e-06	9.07e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—KRAS—pancreatic cancer	3.79e-06	8.95e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—PIK3CA—pancreatic cancer	3.77e-06	8.9e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	3.75e-06	8.87e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CASP3—pancreatic cancer	3.67e-06	8.68e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCND1—pancreatic cancer	3.58e-06	8.45e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CTNNB1—pancreatic cancer	3.54e-06	8.37e-05	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKT1—pancreatic cancer	3.54e-06	8.36e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—HRAS—pancreatic cancer	3.49e-06	8.24e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—PIK3CA—pancreatic cancer	3.48e-06	8.22e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MMP9—pancreatic cancer	3.47e-06	8.21e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PTEN—pancreatic cancer	3.45e-06	8.16e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—HRAS—pancreatic cancer	3.22e-06	7.6e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SRC—pancreatic cancer	3.2e-06	7.57e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VEGFA—pancreatic cancer	3.12e-06	7.37e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—STAT3—pancreatic cancer	3.09e-06	7.3e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NRAS—pancreatic cancer	3.08e-06	7.28e-05	CbGpPWpGaD
Everolimus—MTOR—Immune System—AKT1—pancreatic cancer	3.08e-06	7.27e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CD44—pancreatic cancer	2.91e-06	6.87e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MYC—pancreatic cancer	2.87e-06	6.78e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TGFB1—pancreatic cancer	2.86e-06	6.76e-05	CbGpPWpGaD
Everolimus—MTOR—Disease—AKT1—pancreatic cancer	2.84e-06	6.71e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EGFR—pancreatic cancer	2.81e-06	6.63e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—GCG—pancreatic cancer	2.79e-06	6.58e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KRAS—pancreatic cancer	2.65e-06	6.26e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—STK11—pancreatic cancer	2.62e-06	6.19e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PIK3CA—pancreatic cancer	2.44e-06	5.76e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—pancreatic cancer	2.36e-06	5.57e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—TYMS—pancreatic cancer	2.25e-06	5.32e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HRAS—pancreatic cancer	2.25e-06	5.32e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKT1—pancreatic cancer	1.99e-06	4.7e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—APOE—pancreatic cancer	1.83e-06	4.33e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	1.65e-06	3.91e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PPARG—pancreatic cancer	1.6e-06	3.77e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	1.45e-06	3.44e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	1.27e-06	2.99e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS2—pancreatic cancer	1.26e-06	2.97e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTEN—pancreatic cancer	1.1e-06	2.59e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	7.73e-07	1.83e-05	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—AKT1—pancreatic cancer	6.31e-07	1.49e-05	CbGpPWpGaD
